<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papatheodoridis, G. V.</style></author><author><style face="normal" font="default" size="100%">Dalekos, Gn</style></author><author><style face="normal" font="default" size="100%">Idilman, R.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Van Boemmel, F.</style></author><author><style face="normal" font="default" size="100%">Buti, M.</style></author><author><style face="normal" font="default" size="100%">Calleja, J. L.</style></author><author><style face="normal" font="default" size="100%">Goulis, J.</style></author><author><style face="normal" font="default" size="100%">Manolakopoulos, S.</style></author><author><style face="normal" font="default" size="100%">Loglio, A.</style></author><author><style face="normal" font="default" size="100%">Papatheodoridi, M.</style></author><author><style face="normal" font="default" size="100%">N Gatselis</style></author><author><style face="normal" font="default" size="100%">Veelken, R.</style></author><author><style face="normal" font="default" size="100%">Lopez-Gomez, M.</style></author><author><style face="normal" font="default" size="100%">Hansen, B. E.</style></author><author><style face="normal" font="default" size="100%">Savvidou, S.</style></author><author><style face="normal" font="default" size="100%">Kourikou, A.</style></author><author><style face="normal" font="default" size="100%">Vlachogiannakos, J.</style></author><author><style face="normal" font="default" size="100%">Galanis, K.</style></author><author><style face="normal" font="default" size="100%">Yurdaydin, C.</style></author><author><style face="normal" font="default" size="100%">Esteban, R.</style></author><author><style face="normal" font="default" size="100%">Janssen, H.</style></author><author><style face="normal" font="default" size="100%">Berg, T</style></author><author><style face="normal" font="default" size="100%">Lampertico, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B</style></title><secondary-title><style face="normal" font="default" size="100%">J Hepatol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cirrhosis</style></keyword><keyword><style  face="normal" font="default" size="100%">liver cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">liver stiffness</style></keyword><keyword><style  face="normal" font="default" size="100%">nucleoside analogue</style></keyword><keyword><style  face="normal" font="default" size="100%">nucleotide analogue</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jun 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1600-0641 (Electronic)0168-8278 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND &amp;amp; AIMS: The incidence of hepatocellular carcinoma (HCC) was recently reported to be lower in Asian chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) than entecavir (ETV), but this finding remains controversial. We assessed whether there was a difference between ETV and TDF treated patients of the well monitored, multicenter European PAGE-B cohort in the HCC incidence and other patient outcomes. METHODS: We included 1935 Caucasians with CHB, with or without compensated cirrhosis, treated with ETV (n=772) or TDF (n=1163) monotherapy. Mean follow-up has been 7.1+/-3.0 years from ETV/TDF onset. RESULTS: The 5-year cumulative HCC incidence was 5.4% in ETV and 6.0% in TDF treated patients (log-rank, P=0.321) without significant difference in any patient subgroup [with or without cirrhosis, naive or experienced to oral antiviral(s) (total, with or without cirrhosis)]. In multivariable Cox regression analyses, the hazard of HCC was similar between ETV and TDF treated patients after adjustment for several HCC risk factors. ETV and TDF treated patients had similar rates of on-therapy biochemical and virological remission, HBsAg loss, liver transplantation and/or death. Elastographic reversion of cirrhosis at year 5 (liver stiffness &amp;lt;12 kPa) was observed in 245/347 (70.6%) patients with pretreatment cirrhosis being more frequent in TDF than ETV treated patients (73.8% vs 61.5%, P=0.038). CONCLUSION: In Caucasian CHB patients, with or without cirrhosis, ETV and TDF long-term monotherapy is associated with similar HCC risk and rates of biochemical and virological remission, HBsAg loss and liver transplantation or death, but TDF seems to result in more frequent elastographic reversion of cirrhosis at year 5.</style></abstract><accession-num><style face="normal" font="default" size="100%">32553667</style></accession-num><notes><style face="normal" font="default" size="100%">Papatheodoridis, George VDalekos, George NIdilman, RamazanSypsa, VanaVan Boemmel, FlorianButi, MariaCalleja, Jose LuisGoulis, JohnManolakopoulos, SpiliosLoglio, AlessandroPapatheodoridi, MargaritaGatselis, NikolaosVeelken, RheaLopez-Gomez, MartaHansen, Bettina ESavvidou, SavvoulaKourikou, AnastasiaVlachogiannakos, JohnGalanis, KostasYurdaydin, CihanEsteban, RafaelJanssen, Harry LABerg, ThomasLampertico, PietroengNetherlands2020/06/20 06:00J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382-2. doi: 10.1016/j.jhep.2020.06.011.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. Electronic address: gepapath@med.uoa.gr.Department of Internal Medicine, Thessalia University Medical School, Larissa, Greece.Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.Department of Hygiene, Epidemiology &amp; Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece.Division of Hepatology, Clinic for Oncology, Gastroenterology, Hepatology, Infectious Diseases and Pneumology, University Clinic Leipzig, Leipzig Germany.Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain.Hospital U Puerta de Hierro, IDIPHIM CIBERehd, Madrid, Spain.4th Department of Internal Medicine, Alpharistotle University of Thessaloniki Medical School, Thessaloniki, Greece.Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 2nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens, Athens, Greece.Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC &quot;A. M. and A. Migliavacca&quot; Center for Liver Disease, Milan, Italy.Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.Department of Gastroenterology &amp; Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; Liver Clinic, Toronto Western &amp; General Hospital, University Health Network, Toronto, ON, Canada.2nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens, Athens, Greece.Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey; Department of Gastroenterology and Hepatology, Koc University Medical School, Istanbul, Turkey.Liver Clinic, Toronto Western &amp; General Hospital, University Health Network, Toronto, ON, Canada.Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC &quot;A. M. and A. Migliavacca&quot; Center for Liver Disease, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</style></auth-address></record></records></xml>